Purpose: The effects of hepatic resection on patients with metastatic tumors from gastric adenocarcinomas are unclear. Therefore, we analyzed early clinical outcomes in patients who underwent surgical resection for hepatic metastases from gastric adenocarcinomas. Materials and Methods: From January 2003 to December 2010, 1,508 patients with primary gastric cancers underwent curative gastric resections at the Korea Cancer Center Hospital. Of these patients, 12 with liver-only metastases underwent curative hepatic resection. Their clinical data were analyzed retrospectively. Results: The median follow-up period was 12.5 months (range, 1~85 months); no operative mortalities or major complications were observed. Three patients underwent synchronous resections, and 9 underwent metachronous resections. In the latter group, the median interval between gastrectomy and hepatectomy for hepatic metastasis was 10.5 months (range, 5~47 months). The overall 1-and 5-year survival rates of these 12 patients were 65% and 39%, respectively, with a median overall survival of 31.0 months; 2 patients survived for >5 years. Conclusions: Hepatic resection can be a feasible procedure for treating hepatic metastases from gastric adenocarcinomas. Although this study was small and involved only selected cases, the outcomes of the hepatic resections were comparable and long-term (>5 years) survivors were identified. Surgical resection of the liver can be considered a feasible option in managing hepatic metastases from gastric adenocarcinomas.
Introduction
Gastric adenocarcinomas are common malignancies worldwide.
Over several decades, the management of gastric adenocarcinoma has advanced, and patient prognosis has improved. The proportion of patients with early stage cancers who are being treated is increasing due to the prevalence of more comprehensive surveillance programs. In addition, the advancement of surgical techniques and the development of chemotherapy involving various molecular targeting agents have led to improved prognoses for these patients.
However, several challenging problems remain in the management of gastric cancer.
The liver is the most common site of metastasis in gastrointestinal malignancies and the management of liver metastasis is difficult, and the outcomes are still poor. After curative resection of primary gastric adenocarcinomas, 3.5~14.0% of patients experience intrahepatic recurrence. [1] [2] [3] [4] [5] [6] [7] [8] [9] Most of these patients have multiple forms of intrahepatic and extrahepatic recurrences, including peritoneal carcinomatosis, lymph node metastasis, and direct tumor invasion of other organs. 10, 11 To manage hepatic metastases from gastric adenocarcinomas, various treatment modalities have been introduced, such as systemic chemotherapy and local treatments.
Although systemic chemotherapy with the new molecular targeting agents is the standard treatment modality, the outcomes remain disappointing and the management of hepatic metastasis remains challenging. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Over the past 3 decades, the management of hepatic metastases associated with colorectal adenocarcinomas has advanced, markedly. Many studies have reported the role of hepatic resection for these metastases, and hepatic resection is now associated with a 5-year survival rate of 30~50%. 19, 20 Thus, hepatic resection for hepatic metastases from colorectal adenocarcinoma is currently regarded as one of the standard modalities in multi-disciplinary treatments.
Only a few reports of hepatic resection have been reported for hepatic metastases in cases of gastric adenocarcinomas. Some of these have reported long-term survival and outcomes comparable to those associated with colorectal adenocarcinoma, even though they were small case studies. 5, 6, [12] [13] [14] [15] 
Results
A total of 12 patients (11 men and 1 woman) underwent hepatic resection for hepatic metastases from gastric adenocarcinomas.
Their median age, at the time of hepatic resection, was 61 years (range, 51~74 years), and their median post-resection follow-up period was 12.5 months (range, 1~85 months) ( Table 1) .
Eleven patients had a single hepatic metastasis and underwent hepatic resection, only; one patient had 2 intrahepatic lesions and underwent both hepatic resection and intraoperative radiofrequency ablation. None of the patients died or experienced major complications because of the surgery. Synchronous resections were performed on 3 patients, metachronous resections were performed 9 patients. Five patients received systemic adjuvant chemotherapy after the resection, and 7 did not ( Table 2) .
For the 9 patients who underwent metachronous resection, the median interval between gastrectomy and hepatectomy was 10.5 months (range, 5~47 months). The overall 1-and 5-year survival rates of the 12 patients were 65% and 39%, respectively, with a median survival time of 31.0 months (Fig. 1) . The overall 3-year survival rates for patients who underwent synchronous and metachronous resections were 33% and 38%, respectively; this difference was not statistically significant (P=0.596, Fig. 2 ).
To determine the prognostic factors, a univariate analysis was performed. The TNM stage of the primary gastric cancer, the size of metastatic liver tumor, the type of metastasis (synchronous or metachronous), and the use of systemic adjuvant chemotherapy after hepatic resection did not have a significant impact on survival among the 12 patients (Table 3 ).
Two of the 12 patients survived for more than 5 years after hepatic resection. Both had undergone metachronous hepatic resection, with intervals between gastrectomy and hepatectomy of 12 or 47 months. The pathologic stages of these primary gastric cancers were T3N0M0 and T3N2M0. Both patients had solitary hepatic lesion and both underwent right hemihepatectomy.
One patient who underwent hepatic resection plus intraoperative radiofrequency ablation experienced a new intrahepatic recurrence 8 months later. This patient underwent additional radiofrequency ablation for this lesion and was still living 12 months after the initial hepatic resection.
Discussion
As with other gastrointestinal malignancies, the liver is a common metastatic site for gastric adenocarinomas. After curative resection of a primary gastric adenocarcinoma, 3.5~14.0% of patients experience an intrahepatic recurrence. Therefore, systemic chemotherapy is considered the standard of care, but the median survival time is less than 6 months and longterm survivors are rare. 4, 6 Other treatment modalities have also been applied, such as radiofrequency ablation, hepatic resection, and radiation, but their reported use has been infrequent, and their outcomes have also been disappointing.
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There have been some recent changes in the management of liver metastases associated with gastrointestinal malignancies, especially for those associated with colorectal malignancies. Over several decades, advancements in surgical techniques and postoperative management have improved the safety of liver resections, and newly developed chemotherapeutic molecular targeing agents changed the role of the surgical resection. Liver resection is now one of the multi-disciplinary treatments and play a role in the standard treatment of colorectal liver metastases. 19, 20 Regardless of the use of liver resection for hepatic metastases associated with colorectal cancers, liver resection is still rarely indicated for patients with hepatic metastases from gastric cancers. In previous reports, only 10~20% of patients with hepatic metastases were found to be suitable for surgical treatment, and the outcomes have been also disappointing (median survival, 5~8 months). 2, 11, 14, 16 Recently, a few reports have shown the feasibility of hepatic resections associated with gastric cancer metastases and have noted some long-term survivors. 5, 6, 12, 15 Therefore, selected group of patients, with the proper indications could be helpful in establishing the indications for hepatic resection. The experiences obtained from the management of colorectal liver metastases and the development and the absence of PET-identified extrahepatic lesion. We allowed some exceptions because this study was designed to provide some initial experience and consisted of a retrospective review of patient medical records. The most significant exception was the one patient who included depite having 2 liver lesions indentified. The exception was permitted because the patient had a relatively long diseasefree interval, and one intrahepatic lesion was small and the other lesion was suitable for radiofrequency ablation. We also included 3 patients with synchronous liver metastatic lesions.
Although our study included 12 patients, none of the patients experienced major complicatins or died because of their surgery.
The overall 5-year survival rate, after hepatic resection, was 39%, with a median survival of 31 months; 2 patients survived for ＞5
years. These results suggest that hepatic resection can be a feasible procedure for the managements of hepatic metastases from gastric adenocarcinomas.
The management of hepatic metastases from colorectal cancers and hepatocellular carcinomas has shown that, radiofrequency ablation is a promising method with outcomes similar to those and metachronous metastases have been found to be significant determinants of favorable prognoses after hepatic resection.
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However, we could not find any significant factors that affected survival (Table 3) . Our inability to determine any specific factors that influence survival may have been related to our study's limitations, including the small number of patients and the study's retrospective design. Most of patients had solitary and metachronous hepatic metastases with a long disease-free interval. There were two longterm (＞5 years) survivors in our study. Although not early stage, they had a long interval between gastrectomy and hepatectomy.
This observation may provide a clue for at least one of the indications for resection. Regardless, additional studies are necessary to clarify the role of hepatic resection for metastases from gastric adenocarcinomas.
Hepatic resection can be a feasible procedure for treating hepatic metastases from gastric adenocarcinomas. Although this study was small and involved selected cases, the outcomes of hepatic resections were comparable and long-term (＞5 years) survivors were identified. Surgical resection of the liver can be considered a feasible option in managing hepatic metastases from gastric adenocarcinomas.
